|
|
 |
|
Viewing report
|
|
|
|
Drugs of Tommorrow 2002: Pain
Datamonitor, May 2002
New markets for pipeline drugs will provide the largest growth opportunities across the spectrum of classes used to treat different pain types. For example, the successful uptake of Arcoxia in chronic low back pain will ensure that by 2009 it will be the best selling second-generation Cox-ii inhibitor on the market. Due to the strength and depth of competition in this lucrative market, the need to differentiate or exploit new areas is key to the uptake of all pipeline therapies. This report provides an in-depth analysis of the current pain pipeline. The report profiles drugs currently being developed for the treatment of pain, assessing their clinical trial data, marketing strength, patient potential, and opinion leader insight. The report also looks at the future development of the pain market in terms of forecast sales to 2009, patient potential, as well as future launches of key pipeline products. With a combined analysis of both the current and future markets, the report provides you with a holistic look at the potential of the current pain product pipeline as well as the threats and opportunities associated with this market.
Customers who bought this item also bought
Br Malls Participacoes Sa
Br. Holdings Corporation
The World Market for Butadiene Rubber (BR): A 2009 Global Trade Perspective
The 2009 Import and Export Market for Butadiene Rubber (BR) in Iran
The 2009 Import and Export Market for Butadiene Rubber (BR) in Belarus
The 2009 Import and Export Market for Butadiene Rubber (BR) in Bulgaria
The 2009 Import and Export Market for Butadiene Rubber (BR) in Colombia
The 2009 Import and Export Market for Butadiene Rubber (BR) in Estonia
The 2009 Import and Export Market for Butadiene Rubber (BR) in Slovakia
The 2009 Import and Export Market for Butadiene Rubber (BR) in Turkey
The 2009 Import and Export Market for Butadiene Rubber (BR) in Uruguay
The 2009 Import and Export Market for Butadiene Rubber (BR) in China
|
|
|
|
